Recent Updates
Recently added Catalysts

telehomecare

Phase 1

Congestive Heart Failure | Unknown | Cardiovascular |Johnson & Johnson|Last Updated: Jul 27, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedUNCONTROLLED
Total Trials1
Total Enrollment290
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00261664Empowering Elders Through TechnologyPHASE1 COMPLETED 290Sep 1, 2003Jul 1, 2005Jul 27, 20111 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Self-management of heart failure
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelSINGLE_GROUP
PurposeTREATMENT
Interventions
NameTypeDescription
telehomecareDEVICE -
Unlock Study Design Details
Eligibility Criteria
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * clinical diagnosis of congestive heart failure * must have telephone line in home Exclusion Criteria: * none

Countries:United States
Unlock Eligibility Criteria